SGLT2 inhibitor series

SGLT2 inhibitorNot analyzed

C-glucoside SGLT2 inhibitors — empagliflozin, dapagliflozin, canagliflozin and sotagliflozin for glycemic and cardiorenal benefit.

Mechanism · SGLT2 inhibitor BioMoa · SGLT2 inhibitor BioMoa bridge · shared ID

No analysis recorded yet · 2 weeks cadence · refresh on /analyze · refresh recommended

Data sources: Catalog seed · PubChem · ChEMBL · ClinicalTrials.gov · FDA/EMA
Last updated: Not recorded
Similarity method: Morgan fingerprint, radius 2, 2048 bits, Tanimoto
Verified / known compounds: 4
Exploratory nodes: 1
Abstract scaffolds: 1
Relationship types: Derived (curated) · Fingerprint similarity · Drug-class link

StructureMoa is a chemical-structure exploration tool. Structural similarity, clustering, and SAR relationships are intended for research exploration and do not establish shared potency, selectivity, safety, efficacy, or clinical performance.

Spider Web · Flow · Structure table · Compare · SMILES map

Name, 2D structure, SMILES, role, parent, core similarity, and traits. Click a row for details.

Compound	Role	SMILES	Parent	Core sim.	Traits
C-glucoside SGLT2 pharmacophoreAbstract pharmacophoresglt2-c-glucoside-corePage	Scaffold	`CCOC1=CC=C(C=C1)CC2=CC=C(C=C2)C3OC(CO)C(O)…`	—	—	SGLT2 · core · C-glucoside · Shared pharmacophore / core scaffold. Anchor for the SGLT2 inhibitor series lineage.
Canagliflozin (Invokana)Verified drugcanagliflozinPage	Drug	`CCOC1=CC=C(C=C1)CC2=CC(=CC(=C2)C3=CC=C(C=C…`	C-glucoside SGLT2 pharmacophore	—	SGLT2 · FDA · approved · T2D · Approved therapeutic. Canagliflozin (Invokana) in this family map.
Dapagliflozin (Farxiga)Verified drugdapagliflozinPage	Drug	`CCOC1=CC=C(C=C1)CC2=CC(=CC(=C2)C3=CC=C(C=C…`	C-glucoside SGLT2 pharmacophore	—	SGLT2 · FDA · approved · T2D · HF · Approved therapeutic. Dapagliflozin (Farxiga) in this family map. · CHEMBL184270 · CID 9887712
Empagliflozin (Jardiance)Verified drugempagliflozinPage	Drug	`CCOC1=CC=C(C=C1)CC2=CC(=CC(=C2)[C@@H](C3=C…`	C-glucoside SGLT2 pharmacophore	—	SGLT2 · FDA · approved · T2D · HF · Approved therapeutic. Empagliflozin (Jardiance) in this family map. · CHEMBL2107830 · CID 11949646
Sotagliflozin (Inpefa)Verified drugsotagliflozinPage	Drug	`CCOC1=CC=C(C=C1)CC2=CC(=CC(=C2)C3=CC=C(C=C…`	C-glucoside SGLT2 pharmacophore	—	SGLT2 · SGLT1 · FDA · approved · dual · Approved therapeutic. Sotagliflozin (Inpefa) in this family map.
Fluoro-aryl C-glucoside analogExploratory analog (rule-generated)sglt2-fluoro-aryl-analogPage	Derivative	`CCOC1=CC=C(C=C1)CC2=CC=C(C=C2)C3OC(CO)C(O)…`	C-glucoside SGLT2 pharmacophore	—	SAR · F-scan · SAR exploration node. Derived analog of parent node in SGLT2 inhibitor series.

Name	Role	Derived from	Sim. to core	Relations	Tags
C-glucoside SGLT2 pharmacophoreAbstract pharmacophore	Scaffold	—	—	derived_from: Empagliflozin (Jardiance) · derived_from: Dapagliflozin (Farxiga) · derived_from: Canagliflozin (Invokana) · derived_from: Sotagliflozin (Inpefa) · derived_from: Fluoro-aryl C-glucoside analog	SGLT2, core, C-glucoside
Canagliflozin (Invokana)Verified drug	Drug	C-glucoside SGLT2 pharmacophore	—	derived_from: C-glucoside SGLT2 pharmacophore · similar_to: Dapagliflozin (Farxiga) · related_drug: Sotagliflozin (Inpefa)	SGLT2, FDA, approved, T2D
Dapagliflozin (Farxiga)Verified drug	Drug	C-glucoside SGLT2 pharmacophore	—	derived_from: C-glucoside SGLT2 pharmacophore · similar_to: Empagliflozin (Jardiance) · similar_to: Canagliflozin (Invokana) · similar_to: Sotagliflozin (Inpefa) · related_drug: Empagliflozin (Jardiance)	SGLT2, FDA, approved, T2D, HF
Empagliflozin (Jardiance)Verified drug	Drug	C-glucoside SGLT2 pharmacophore	—	derived_from: C-glucoside SGLT2 pharmacophore · similar_to: Dapagliflozin (Farxiga) · related_drug: Dapagliflozin (Farxiga)	SGLT2, FDA, approved, T2D, HF
Fluoro-aryl C-glucoside analogExploratory analog (rule-generated)	Derivative	C-glucoside SGLT2 pharmacophore	—	derived_from: C-glucoside SGLT2 pharmacophore	SAR, F-scan
Sotagliflozin (Inpefa)Verified drug	Drug	C-glucoside SGLT2 pharmacophore	—	derived_from: C-glucoside SGLT2 pharmacophore · similar_to: Dapagliflozin (Farxiga) · related_drug: Canagliflozin (Invokana)	SGLT2, SGLT1, FDA, approved, dual

Loading map…

Clinical · regulatory context

SGLT2 — 당뇨·심부전·신장

C-glucoside 계열. 혈당 외 HF/CKD 적응증 확장이 핵심입니다.

Approved/clinical labels here come from the catalog clinical overlay. Agency names are shown when curated; live FDA/EMA APIs are not called.

EmpagliflozinApprovedFDA/EMA
T2D, HFrEF/HFpEF, CKD
ClinicalTrials.gov
DapagliflozinApprovedFDA/EMA
T2D, HF, CKD
ClinicalTrials.gov

Program and pipeline notes live on BioMoa · sglt2 · StructureMoa ↔ BioMoa bridge